title: Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.
abstract: Objectives. The aim of this study was to investigate and compare the eradication rate of Helicobacter pylori as the third-line triple therapy with rabeprazole (RPZ) + amoxicillin (AMPC) + levofloxacin (LVFX) and high-dose RPZ + AMPC. Methods. 51 patients who failed Japanese first-line (proton pump inhibitor (PPI) + AMPC + clarithromycin) and second-line (PPI + AMPC + metronidazole) eradication therapy were randomly assigned at a 1 : 1 ratio to one of the following third-line eradication groups: (1) RAL group: RPZ 10 mg (b.i.d.), AMPC 750 mg (b.i.d.), and LVFX 500 mg (o.d.) for 10 days; (2) RA group: RPZ 10 mg (q.i.d.) and AMPC 500 mg (q.i.d.) for 14 days. Patients who failed to respond to third-line eradication therapy received salvage therapy. Results. The rates of eradication success, based on intention to treat (ITT) analysis, were 45.8% in the RAL group and 40.7% in the RA group. The overall eradication rates were 73.9% in the RAL group and 64.0% in the RA group. There was no significant difference between the two groups. Conclusions. The third-line triple therapy with RPZ, AMPC, and LVFX was as effective as that with high-dose RPZ and AMPC.
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Okimoto
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Arai
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Saito
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Shoko
authors.initials: S
authors.lastname: Minemura
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Maruoka
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Matsumura
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Tomoo
authors.initials: T
authors.lastname: Nakagawa
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Katsuno
authors.affiliation: Department of Clinical Laboratory, Chiba University Hospital, Japan.
authors.forename: Chisato
authors.initials: C
authors.lastname: Ishii
authors.affiliation: Department of Clinical Laboratory, Chiba University Hospital, Japan.
authors.forename: Shota
authors.initials: S
authors.lastname: Murata
authors.affiliation: Department of Clinical Laboratory, Chiba University Hospital, Japan.
authors.forename: Masaharu
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Department of Clinical Laboratory, Chiba University Hospital, Japan.
authors.forename: Fumio
authors.initials: F
authors.lastname: Nomura
authors.affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokosuka